49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

573 trials found

diseases per page:

Showing 1 to 10 of 573 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05278663 (ClinicalTrials.gov)	April 30, 2022	4/3/2022	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythema ...	A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Asses ...	Lupus Erythematosus, Systemic	Drug: E6742;Other: Placebo	Eisai Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	24	Phase 1/Phase 2	Japan
2	EUCTR2019-003406-27-DK (EUCTR)	09/03/2022	04/03/2021	A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with modera ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Name: Dapirolizumab pegol Product Code: CDP7657 INN or Proposed INN: Dapirolizumab pegol Other ...	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Serbia;Portugal;Philippines;Taiwan;Greece;Spain;Chile;Colombia;Italy;France;Peru;Austr ...
3	EUCTR2019-003407-35-ES (EUCTR)	09/03/2022	17/01/2022	A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with modera ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Name: Dapirolizumab pegol Product Code: CDP7657 INN or Proposed INN: dapirolizumab pegol Other ...	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Serbia;Portugal;Czechia;Taiwan;Hong Kong;Greece;Spain;Austria;United Kingdom;Italy;Fra ...
4	NCT05123586 (ClinicalTrials.gov)	February 28, 2022	16/11/2021	A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemi ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinic ...	Systemic Lupus Erythematosus	Drug: LY3361237;Drug: Placebo	Eli Lilly and Company	NULL	Not yet recruiting	18 Years	65 Years	All	90	Phase 2	United States;Argentina;Czechia;Mexico;Poland;Puerto Rico;Russian Federation;Ukraine
5	EUCTR2020-004047-86-HU (EUCTR)	28/02/2022	23/12/2021	A Study of ALPN-101 in Active Lupus	A Randomised, Double-Blind, Placebo-controlled study of ALPN-101 in Systemic Lupus Erythematosus	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042946;Term: ...	Product Code: ALPN-101 INN or Proposed INN: Acazicolcept Other descriptive name: ALPN-101	Alpine Immune Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 2	France;United States;Taiwan;Hungary;Spain;Poland;Russian Federation;Germany;Korea, Republic of
6	JPRN-jRCT2011210069	15/02/2022	05/02/2022	A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placeboin Participants With A ...	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy ...	Systemic Lupus Erythematosus	ArmA:BMS-986256 30mg QD ArmB:BMS-986256 10mg QD ArmC:BMS-986256 2.5mg QD ArmD:Placebo QD	Ranganathan Usha	NULL	Recruiting	>= 20age old	<= 70age old	Both	20	Phase 2	Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Mexico;Poland;Romania;Spain;Taiwan; ...
7	NCT05203419 (ClinicalTrials.gov)	February 15, 2022	10/1/2022	Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SL ...	A Two-part, Randomized, Investigator- and Participant- Blinded, Placebo-controlled, Multiple Ascendi ...	Lupus Erythematosus, Systemic	Drug: MHS552;Drug: Placebo	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	65 Years	All	28	Phase 1	NULL
8	JPRN-jRCT2041210058	04/02/2022	20/08/2021	A Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Nipocalimab in ...	Systemic Lupus Erythematosus	Group 1_Placebo:Participants will receive placebointravenously (IV) every two weeks (q2w) through We ...	Numaguchi Hirotaka	NULL	Recruiting	>= 18age old	<= 65age old	Both	225	Phase 2	Bulgaria;Colombia;Germany;Spain;Hungary;Poland;Taiwan, Province Of China;Ukraine;United States OfAme ...
9	NCT05203692 (ClinicalTrials.gov)	February 2, 2022	20/1/2022	A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects	A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Se ...	Systemic Lupus Erythematosus	Drug: DS-7011a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Recruiting	18 Years	45 Years	All	80	Phase 1	United States
10	NCT05140824 (ClinicalTrials.gov)	December 30, 2021	4/11/2021	A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in P ...	A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the ...	Systemic Lupus Erythematosus (SLE)	Drug: Placebo;Biological: TJ202 injection	I-Mab Biopharma Co. Ltd.	NULL	Recruiting	18 Years	65 Years	All	72	Phase 1	China

First Previous1 2 3 4 5…58Next Last